Septerna, Inc. has recently filed a report detailing stock sales by Chief Financial Officer Gil M. Labrucherie. This development is significant as it reflects the company's ongoing financial strategies and may impact investor perceptions.
Septerna, Inc., classified under the Standard Industrial Classification (SIC) code 2834, specializes in pharmaceutical preparations. The company trades on the Nasdaq under the ticker SEPN. Its recent filings indicate active management and potential shifts in ownership dynamics.
The filing reveals that Labrucherie sold a total of 19,000 shares on November 16, 2026, at prices ranging from approximately $40.85 to $43 per share. The transactions were executed under a Rule 10b5-1 sales plan adopted earlier in the year, which allows for predetermined sales of stock to avoid potential insider trading violations. Following these sales, Labrucherie retains ownership of 7,002 shares.
This update may affect various stakeholders, including investors and analysts monitoring Septerna's financial health and strategic direction. The pharmaceutical preparations sector is highly competitive, and such sales can signal confidence or concerns about the company's future performance.
The filing does not specify what actions will follow these transactions, leaving investors and market watchers to speculate on the implications for Septerna's growth trajectory.
Details of the Transactions
The filing outlines three separate transactions by Labrucherie on November 16, 2026. The first transaction involved the sale of 15,815 shares at a weighted average price of approximately $41.48, with the shares sold in multiple transactions at prices ranging from $40.85 to $41.845. Following this transaction, Labrucherie retained ownership of 24,185 shares.
The second transaction consisted of selling 3,485 shares at a weighted average price of about $41.99, with prices ranging from $41.85 to $42.14. After this sale, his ownership decreased to 20,700 shares.
Lastly, Labrucherie sold 700 shares at a price of $43 per share, resulting in a remaining ownership of 20,000 shares. Notably, all shares sold were held in trust, specifically by The Labrucherie Trust dated September 1, 2009, for which Labrucherie serves as trustee.
"The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any."
Context of the Sales
The transactions were executed under a Rule 10b5-1 sales plan adopted on July 22, 2026, which is designed to provide a safe harbor for insiders to sell shares without the risk of insider trading allegations. This plan reflects a strategic approach to managing stock sales while adhering to regulatory requirements.
Additionally, the filing indicates that Labrucherie's remaining shares include 3,501 shares acquired under the Septerna, Inc. 2024 Employee Stock Purchase Plan on October 31, 2025, and another 3,501 shares acquired under the same plan on April 30, 2026, which were exempt from reporting under Rule 16b-3(c).
Implications for Stakeholders
These transactions may provide insights into Labrucherie's confidence in Septerna's future, as well as the company's liquidity and stock performance. Stakeholders may interpret the sales as a sign of strategic financial planning, particularly in the context of the competitive pharmaceutical sector.
However, the filing does not provide any details regarding future plans for the company or any anticipated changes in leadership or strategy following these transactions.
Read Next
Regazzi acquires 15,000 options at Research Solutions, Inc.
Zachary M. Stern sells 75,000 shares of Constellation Brands
Kenneth L. Gayron files Form 4 with limited details
Research Solutions director acquires 12,500 stock options
Ellis Stephen A disposes of 21,928 shares in Schwab Corp
Abigail J. Bennett sells 75,000 shares of Constellation Brands




